Details of HTA journal title
Research type: |
NICE Technology Assessment Report (TAR) |
Title (lead author) etc: |
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation (Rodgers) 134 pages, Volume 15, number 10 |
Link to NICE guidance page |
|
DOI |
10.3310/hta15100 |
View/print executive summary
View/print abstract
View full text in pdf format (1793 KB) View separate 195 page appendix in pdf format (1926 KB)The appendix is only available electronically. It is not available in the printed version.
Outputs from this project
Go to our correspondence page to comment on this publication
|
|
Headline: |
Review found that etanercept, infliximab and adalimumab are efficacious in the treatment of psoriatic arthritis compared with placebo, with beneficial effects on joint symptoms, functional status and skin. Length of follow-up in trials was limited but the evidence to support the use of these biologic agents is convincing, given the size of treatment effect and quality of the data |
This report should be referenced as follows: |
Rodgers M, Epstein D, Bojke L, Yang H, Craig D, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10). |
Project ref: |
08/42/01 |
Original project title: |
The clinical and cost effectiveness of etanercept, infliximab and adalimumab - psoriatic arthritis (guidance review 104 and 125) |
Chief Investigator: |
Centre for Reviews and Dissemination (CRD), University of York |
Start Date: |
June 2009 |
Date of publication in HTA journal series |
February 2011 |
Cost: |
This project was commissioned by the HTA programme on behalf of the National Institute for Health and Clinical Excellence on a call-off contract basis |
Project Protocol: |
Project protocol not available |
Printed copies of this title despatched: |
109 (Figures relate to the previous calendar month) |
URL of this page: |
http://www.hta.ac.uk/2053 |
Sorry - this title is now out of print.
News feeds